List of Fellows

Yannick Devaud* and his team are working on a minimally invasive surgical device for precise application of bioadhesives to prevent membrane rupture after fetoscopy. Recent development in pre-natal diagnosis enables the detection of life-threatening congenital diseases on fetuses during the pregnancy. The minimally invasive interventions in the womb, called fetoscopies, come along with a high risk of preterm birth related to the perforation of the fetal membrane needed for the insertion of the medical instruments. This important collateral effect is a critical limitation for those fetoscopies and for development of more sophisticated fetal surgeries. Yannick's innovative technology aims to prevent iPPROM through the sealing of the site of puncture with an implantable medical device at the end of the fetal surgery. This will help to fight against fetal morbidity and mortality resulting from prenatal treatments and open a new horizon in the fetal treatment field.

*Laboratory for Cell and Tissue Engineering, Martin Ehrbar

Yannick Team
Team from left to right: Prof. Roland Zimmermann, Prof. Nicole Ochsenbein-Kölble, Dr. Yannick Devaud, PD Dr. Martin Ehrbar (Image: Devaud)


Josua Jordi* and his team target on a novel therapeutic approach to treat pandemic obesity and its comorbidities. Both remain a major burden for the billions of affected individuals because the current anti-obesity medical therapy is unsatisfactory in terms of efficacy and safety. His team identified a set of small molecules with remarkable in vivo potency and selectivity i.e. absence of side-effects in two vertebrate models. Currently, we aim to solidify the promising candidate compounds using pre-clinical obesity models and set herewith the stage for their clinical development.

*Institute of Veterinary Physiology, Prof. Thomas Lutz

Jordi Team
Team from left to right: Dr. Josua Jordi, Prof. Thomas Lutz (Image: Jordi)


Pawl Sledz* and his team will provide the proof of concept for therapeutic value of targeting epitranscriptomics modification machinery for cancer therapy. Epitranscriptomics (RNA epigenetics) has emerged recently as relatively novel and unexplored regulation mechanism of gene expression in the cell, which in some cases can be the driving factor behind cancer. His team has deployed a computationally driven drug discovery platform focused on targeting RNA modifications, which he is now applying to deliver first small molecules modulating the epitranscriptomic regulation machinery.

*Department of Biochemistry, Prof. Amedeo Caflisch

Pawel Team
Team from left to right: Prof. Amedeo Caflisch, Lars Wiedmer, Danzhi Huang, Yaozong Li, Rajiv Bedi, Pawel Sledz, not in the picture: Stefanie Eberle (Image: Sledz)


Gabriele Gut* and his team are working towards establishing a personalized medicine platform for cancer diagnosis and therapy selection. Whilst Genomics – based diagnosis of a patient’s disease is becoming ever more common practice in the era of personalized medicine; Gabriele and his team, however, envision to provide health-care professionals with a patient-tailored report containing therapy recommendations based on molecular profiling of a patient’s tumour cells before and after ex-vivo drug testing and novel tissue section diagnostics.

*Institute of Molecular Life Sciences, Prof. Lucas Pelkmans


Jane Beil-Wagner* and her team aim to establish an in vitro production system for PMSG.  Pregnant mare serum gonadotropin has many uses in reproductive biology and is central to infertility treatments, laboratory animal science and most importantly breeding management of livestock. It is isolated from the blood of pregnant horses in so-called "blood farms" in South America, where the horses are kept under unethical conditions. To protect these animals and to overcome current shortage in the PMSG supply novel solutions are needed.

*Institute of Laboratory Animal Science, Prof. Thorsten Buch

Team Jane Beil-Wagner
Team from left to right: Dr. Iana Buch, Dr. Sabine Specht, Dr. Jane Beil-Wagner (Bild: Beil-Wagner)

Stefan Kleiser* is working on “Translating a novel oximeter to clinical use”. Together with his team he takes the next steps from a highly precise research tissue oximeter towards a medical device improving intensive care by avoiding oxygen undersupply and brain damage. The translation of OxyPrem will be focused on user needs and industrialized manufacturing, in close linkage and cooperation with later customers. This project paves the ground towards medical application of the instrument enabling clinicians to diagnose more precisely, improving patient outcomes.

*Biomedical Optics Research Laboratory / Neonatology, Prof. Martin Wolf

Team Kleiser
Team from left to right: Daniel Ostojic, Alexander Nitsch, Dr. Stefan Kleiser, Prof. Dr. Martin Wolf (Bild: Kleiser)


Denis Schapiro* is working on "Automatic identification of stratifying signatures in cancer using topographic biomarkers". His team has created an interactive computational tool box «histoCAT» (histology topography cytometry analysis toolbox) to combine Cytometry and Pathology in a user-friendly manner so that pathologists and ideally patients can benefit from the comprehensive analysis of spatial structures in tissue architecture. They propose to extent their computational framework as a platform for biomarker discovery based on spatial localization of cell types, tissue organization and cellular neighborhoods – topographic biomarkers.

*Institute of Molecular Life Sciences, Prof. Bernd Bodenmiller

Team from left to right: Dr. Denis Schapiro, Prof. Dr. Bernd Bodenmiller, Dr. Hartland Jackson (Bild Schapiro)


Iwan Zimmermann* is working on "Therapeutic nanobodies against multidrug resistant Escherichia coli". Together with his team they aim to build a unique technology plattform to develop a new antibiotic to treat multidrug resistant E. coli. Unlike marketed small-molecule antibiotics, non-pathogenic bacteria in the gut will remain unaffected by the new treatment, which counteracts the spread of antibiotic resistance. The new class of antibiotics emanating from this drug discovery program will thus not only be a valuable treatment option for life-threatening conditions, it will also allow for a spatial and temporal antibiotic precision that has never been achieved before, thus minimizing the occurrence of new multi-resistant strains.

*Institue of Medical Microbiology, Prof. Markus Seeger

Team Zimmermann
Team from left to right: Dr. Pascal Egloff, Prof. Dr. Markus Seeger, Dr. Iwan Zimmermann (Bild: Zimmerman)